Deals of the day-Mergers and acquisitions

Published on 06/16/2025 at 16:12

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Supernus Pharmaceuticals, Inc.

Sector Update: Health Care Stocks Rise in Late Afternoon Trading	Jul. 01	MT
Sector Update: Health Care Stocks Advance Tuesday Afternoon	Jul. 01	MT
Sage Therapeutics to Cut Most Jobs Following Acquisition by Supernus Pharmaceuticals	Jul. 01	MT
Supernus Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 06, 2025	Jun. 23
Deals of the day-Mergers and acquisitions	Jun. 16	RE
Sector Update: Health Care Stocks Retreat Late Afternoon	Jun. 16	MT
Sector Update: Health Care Stocks Softer Monday Afternoon	Jun. 16	MT
Supernus Pharmaceuticals, Inc., Sage Therapeutics, Inc. - M&A Call	Jun. 16
Top Midday Stories: Equity Markets Rise on Hopes of Containment of Israel-Iran Hostilities; Meta to Introduce Ads on WhatsApp	Jun. 16	MT
Supernus enters depression drug market with up to $795 million Sage deal	Jun. 16	RE
Deals of the day-Mergers and acquisitions	Jun. 16	RE
Sector Update: Health Care Stocks Flat to Higher Premarket Monday	Jun. 16	MT
Wedbush Adjusts PT on SAGE Therapeutics to $8.50 From $6 on Heels of Announced Sale to Supernus; Maintains Neutral	Jun. 16	MT
Supernus Pharmaceuticals To Acquire Sage Therapeutics, Strengthening Its Neuropsychiatry Product Portfolio	Jun. 16	RE
Supernus Pharmaceuticals to Acquire Sage for Up to $795 Million in Cash	Jun. 16	MT
Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal	Jun. 16	RE
Supernus Pharmaceuticals, Inc. Announces Paragraph IV ANDA Filings for Qelbree®?	May. 28	CI
Earnings Flash (SUPN) Supernus Pharmaceuticals Q1 Loss Per Share $0.21 Vs. FactSet Est. Loss $0.01	May. 06	MT
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 06	CI
Earnings Flash (SUPN) Supernus Pharma Q1 Revenue $149.8 Million Vs. FactSet Est. $147.9 Million	May. 06	MT
Earnings Flash (SUPN) Supernus Pharmaceuticals Reports Q1 Revenue $149.8M, vs. FactSet Est of $147.9M	May. 06	MT
Supernus Pharmaceuticals, Inc. Reiterates Earnings Guidance for Full Year 2025	May. 06	CI
Axsome's ADHD drug meets main goal in late-stage study	Mar. 25	RE
Supernus Pharmaceuticals, Inc. Presents at Barclays 27th Annual Global Healthcare Conference 2025, Mar-11-2025 12:30 PM	Mar. 11
Supernus Pharmaceuticals Q4 Earnings, Revenue Rise; Provides 2025 Revenue Guidance	Feb. 26	MT